MEDNAX Inc. (
Q3 2011 Earnings Conference Call
November 1, 2011 10:00 AM ET
David Parker – VP, IR
Roger Medel – Director and CEO
Vivian Lopez-Blanco – CFO
Karl Wagner – President, American Anesthesiology
Brian Zimmerman – Deutsche Bank
Joanna Gajuk – Bank of America
Ryan Daniels – William Blair
Bill Bonello – RBC Capital Markets
Robert Mains – Morgan Keegan
Ralph Giacobbe – Credit Suisse
Kevin Ellich – Piper Jaffray
Brooks O'Neill – Dougherty & Company
Matt Weight – Feltl & Company
Ladies and gentlemen, thank you for standing by. Welcome to the MEDNAX 2011 third quarter earnings call. For the conference all the participants are in a listen-only mode. There will be an opportunity for your questions instructions will be given at that time (Operator Instructions) and as a reminder, this call is being recorded.
Now that been said, I'll turn the conference now to the Vice President of Investor Relations Mr. David Parker. Please go ahead.
Thank you, John and good morning everyone. Certain statements and information presenting during this conference call may contain forward-looking statements. These forward-looking statements are based on assumptions and assessments made by MEDNAX's management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.
Any forward-looking statements made during this call are made as of today, and MEDNAX undertakes no duty to update or revise any such statements whether as a result of new information, future events or otherwise. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the company's most recent annual report on Form 10-K, including the sections entitled Risk Factors, which is available on the Investors page of our website, www.mednax.com.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts